SWTX SpringWorks Therapeutics

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will present at the following upcoming investor conferences:

  • 2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.
  • Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.
  • Barclays Global Healthcare Conference on Wednesday, March 16 from 9:30-10:00 am ET.

Webcasts of these events will be available on the Events & Presentations page within the Investors & Media section of the company’s website at . Replays of the webcasts will be available on SpringWorks’ website for a limited time following each conference.

About SpringWorks Therapeutics

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing 17 development programs, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio and create more solutions for patients with cancer. For more information, visit and follow @SpringWorksTx on and .

SpringWorks Contacts:

Kim Diamond

Vice President, Communications and Investor Relations

Phone: 203-561-1646

Email:

Samantha Hilson Sandler

Director, Investor Relations

Phone: 203-461-5501

Email:



EN
01/02/2022

Underlying

SWTXSpringWorks Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SpringWorks Therapeutics

 PRESS RELEASE
Free
SWTX SpringWorks The...

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy a...

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology – Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile –  STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that long-term efficacy and sa...

October 21, 2025 1 EN
 PRESS RELEASE
Free
SWTX SpringWorks The...

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy a...

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long...

October 21, 2025 1 EN
 PRESS RELEASE
Free
SWTX SpringWorks The...

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the...

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatme...

August 18, 2025 1 EN
 PRESS RELEASE
Free
SWTX SpringWorks The...

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the...

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who...

August 18, 2025 1 EN
 PRESS RELEASE
Free
SWTX SpringWorks The...

European Commission Grants Conditional Approval of EZMEKLY® (mirdameti...

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN – EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of symptoma...

July 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch